Bausch Health Companies Inc. (NYSE:BHC) Receives Average Recommendation of “Buy” from Analysts

Bausch Health Companies Inc. (NYSE:BHCGet Rating) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $21.60.

BHC has been the subject of a number of research analyst reports. Royal Bank of Canada lowered their price target on Bausch Health Companies from $32.00 to $21.00 and set an “outperform” rating for the company in a report on Monday, May 9th. Bank of America lowered their price target on Bausch Health Companies from $25.00 to $12.00 in a report on Wednesday. StockNews.com cut Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Wednesday. BMO Capital Markets lowered their price target on Bausch Health Companies from $26.00 to $15.00 in a report on Wednesday. Finally, TheStreet cut Bausch Health Companies from a “c-” rating to a “d+” rating in a report on Monday, March 28th.

NYSE:BHC opened at $10.84 on Friday. The stock has a fifty day moving average price of $20.85 and a 200-day moving average price of $23.99. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -9.51, a PEG ratio of 0.20 and a beta of 1.62. Bausch Health Companies has a fifty-two week low of $7.80 and a fifty-two week high of $32.54.

Bausch Health Companies (NYSE:BHCGet Rating) last released its earnings results on Wednesday, February 23rd. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.19. The firm had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.21 billion. Bausch Health Companies had a negative return on equity of 649.29% and a negative net margin of 4.89%. The company’s revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.33 EPS. On average, analysts expect that Bausch Health Companies will post 4.25 EPS for the current fiscal year.

In other news, insider Joseph F. Gordon sold 3,889 shares of the stock in a transaction dated Tuesday, March 8th. The stock was sold at an average price of $21.76, for a total value of $84,624.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Spurr sold 1,595 shares of the company’s stock in a transaction dated Thursday, April 14th. The shares were sold at an average price of $22.19, for a total value of $35,393.05. Following the sale, the insider now owns 90,506 shares in the company, valued at approximately $2,008,328.14. The disclosure for this sale can be found here. In the last three months, insiders sold 16,668 shares of company stock valued at $378,570. Insiders own 13.75% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP bought a new stake in shares of Bausch Health Companies during the 3rd quarter valued at about $1,255,000. National Bank of Canada FI bought a new position in Bausch Health Companies in the fourth quarter worth approximately $4,525,000. Fifth Third Bancorp boosted its holdings in Bausch Health Companies by 296.0% in the fourth quarter. Fifth Third Bancorp now owns 4,348 shares of the company’s stock worth $120,000 after acquiring an additional 3,250 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Bausch Health Companies by 2.1% in the third quarter. Handelsbanken Fonder AB now owns 54,200 shares of the company’s stock worth $1,509,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Bausch Health Companies by 11.3% in the third quarter. Franklin Resources Inc. now owns 208,624 shares of the company’s stock worth $5,810,000 after acquiring an additional 21,180 shares in the last quarter. Institutional investors own 73.38% of the company’s stock.

About Bausch Health Companies (Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Further Reading

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.